Substituted quinolines for the treatment of protozoa and retrovirus co-infections
US7342026B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jan 15, 2002 |
| Grant date | Mar 11, 2008 |
| Priority date | — |
| Expiry date | Feb 13, 2024 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to the use of quinolines having general formula (I), wherein R1 denotes H; alkyl C1-C15; alkenyl or alkynyl C2-C15; —CHO; heteroaryl; alkyl C1-C15 or alkenyl or alkynyl C2-C7 comprising at least one substituent selected from among O, halogen, —OH, —CHO, —COOH, aryloxycarbonyl, alkyloxycarbonyl C2-C8, alkenyloxycarbonyl C3-C9, nitrile, aryl, heteroaryl, arylsulphone, alkylsulphone C1-C7, thioalkyl or aminoalkyl C1-C7; alkenyl C2-C 7 bearing at least one substituent selected from among NH2, aleoxy C1-C7, phenoxy, cycloakyl C3-C6 or heteroaryloxy, alkenyl or alkynyl C2-C15 comprising at least one trialkylsilyl C1-C7; R2, in position 3, 6 or 8, denotes H; halogen; —OH; —CHO; —COOH; alkyl or aleoxy C1-C7; —NH2; alkenyl C2-C7; or alkynyl C2-C10; R1 and R2 do not both denote H. The invention is used for the preparation of a medicine to treat protozoan and retrovirus co-infections
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.